Efficacy and Safety of Rituximab in the Treatment of Anti-Vimentin Antibody-associated Diseases
Clinical trial NCT07051070 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07051070
- Sponsor
- Xuanwu Hospital, Beijing
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-01
- Primary completion
- 2026-10-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.